Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1,3-butadiene-induced mouse lymphomas

Cancer Letters

Volumn 152, Issue 2, 2000, Pages 129-134

  Zhuang, Shi Mei ^a   Wiseman, Roger W ^b   Söderkvist, Peter ^a  

^a Fac Hlth S   (Sweden)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

1,3 Butadiene; 2',3' Dideoxycytidine; Ccnd1; Cdk4; pRb pathway; Rb1

Indexed keywords

1,3 BUTADIENE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; ZALCITABINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE PHASE; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING;

ANIMALS; BLOTTING, SOUTHERN; BUTADIENES; CARCINOGENS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DNA MUTATIONAL ANALYSIS; GENES, RETINOBLASTOMA; LYMPHOMA; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; ZALCITABINE;

EID: 0034194563     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00447-4     Document Type: Article

References (24)

1. Hall M., Peters G. Genetic alterations of cyclins, cyclin-depentent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
2. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
3. Strauss M., Lukas J., Bartek J. Unrestricted cell cycle and cancer. Nat. Med. 1:1995;1245-1246.
4. Sherr C.J. Cancer cell cycle. Science. 274:1996;1672-1677.
5. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 8:1996;805-814.
6. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
7. Mittnacht S. Control of pRb phosphorylation. Curr. Opin. Genet. Dev. 8:1998;21-27.
8. Serrano M., Hannon G.J., Beach D. new regulator motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
9. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 371:1994;257-261.
10. Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. 147:1995;545-560.
11. Cairns P., Polascik T.J., Eby Y., Tokono K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., Rutter J.L., Buckler A., Gabrielson E., Tockman M., Cho K.R., Hedrick L., Bova G.S., Isaacs W., Koch W., Schwab D., Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11:1995;210-212.
12. INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood. 87:1996;4949-4958.
13. Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F., Zeuthen J., Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional units frequently altered in melanoma pathogenesis. Cancer Res. 56:1996;5475-5483.
14. IARC. 1,3-butadiene. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 54 (1992) 237-285.
15. Starnes M.C., Cheng Y.C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262:1987;988-991.
16. Melnick R.L., Huff J., Chou B.J., Miller R.A. Carcinogenicity of 1,3-butadiene in C57BL/6 × C3H F1 mice at low exposure concentrations. Cancer Res. 50:1990;6592-6599.
17. Rao G.N., Collins B.J., Giles H.D., Heath J.E., Foley J.F., May R.D., Buckley L.A. Carcinogenicity of 2′,3′-dideoxycytidine in mice. Cancer Res. 56:1996;4666-4672.
18. INK4b genes in 2′,3′-dideoxycytidine- and 1,3-butadiene-induced lymphomas. Oncogene. 16:1998;803-808.
19. Zhuang S.-M., Cochran C., Goodrow T., Wiseman R.W., Söderkvist P. Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2′,3′-dideoxycytidine- induced lymphomas. Cancer Res. 57:1997;2710-2714.
20. Zhuang S.-M., Eklund L.K., Cochran C., Rao G.N., Wiseman R.W., Söderkvist P. Allelotype analysis of 2′,3′-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice. Cancer Res. 56:1996;3338-3343.
21. Schimidt E.E., Ichimura K., Reifenberger G., Collins P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:1994;6321-6324.
22. Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C.J., Look A.T. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res. 53:1993;5535-5541.
23. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281-1284.
24. Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J., Hayward N., Dracopoli N.C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12:1996;97-99.